Evidence map›Paper›PMID 42818274›Full record

ArticlebioRxiv : the preprint server for biology2026

The HBV basal core promoter mutation confers a replicative advantage and transcriptionally reprograms hepatocytes toward HCC subtypes.

Leon L Seifert, Georgios Dangas, Hoyin Chu, Yingpu Yu, Kosuke Ogata, Xupeng Hong, Mengyin Zhang, Yichen Zhou, Chenhui Zou, Alireza Ramandi and 15 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Leon L SeifertLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-0089-7669
Georgios DangasLaboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University, Atlanta, GA, USA.ORCID 0009-0003-3771-1279
Hoyin ChuComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8630-3667
Yingpu YuLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-4837-5744
Kosuke OgataDepartment of Molecular Systems BioAnalysis, Kyoto University, Kyoto, Japan.ORCID 0000-0002-0634-3990
Xupeng HongLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-7091-6108
Mengyin ZhangLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-3316-8267
Yichen ZhouLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Chenhui ZouLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Alireza RamandiDivision of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-8247-4258
Corrine QuirkLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Evgenia MoschogianniLaboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University, Atlanta, GA, USA.ORCID 0009-0008-0375-9633
Catherine A FreijeLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0002-1939-3102
Antonis AthanasiadisLaboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University, Atlanta, GA, USA.ORCID 0009-0000-6268-6683
Leonardo GonzalesDepartment of Pathology, NYU School of Medicine, New York, NY, USA.ORCID 0009-0006-9422-708X
Luis ChiribogaDepartment of Pathology, NYU School of Medicine, New York, NY, USA.ORCID 0000-0002-2028-6873
Clifton FulmerDepartment of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0003-1453-9421
Hong HurDepartment of Research Bioinformatics, Center for Clinical and Translational Science, The Rockefeller University Hospital, New York, NY, USA.ORCID 0000-0002-4088-9188
Manoj KandpalDepartment of Research Bioinformatics, Center for Clinical and Translational Science, The Rockefeller University Hospital, New York, NY, USA.ORCID 0000-0002-0595-8627
Anna S LokDepartment of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0002-5811-6845
Caleb LareauComputational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4179-4807
William M SchneiderLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Charles M RiceLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0003-3087-8079
Eleftherios MichailidisLaboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University, Atlanta, GA, USA.ORCID 0000-0002-9907-4346
Ype P de JongLaboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.ORCID 0000-0001-6357-2370

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Enhancing immune regulation in gene therapy for hemophiliaR01HL131093 · NHLBI · UNIVERSITY OF FLORIDA · PI Ype Peter De Jong, Roland W. Herzog · 2016 to 2026
$7.2M
The Human DNA virome: from petabase scale to single-cell resolutionU01AT012984 · NCCIH · SLOAN-KETTERING INST CAN RESEARCH · PI Caleb Andrew Lareau · 2024 to 2026
$5.2M
Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biologyR01AI150275 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2020 to 2026
$4.4M
Breaching the species barrier: Towards an immunocompetent HBV-susceptible mouse modelR01AI183884 · NIAID · ROCKEFELLER UNIVERSITY · PI Charles M Rice · 2024 to 2026
$2.4M
A proteomics atlas of HIV/HBV infections for curing HBVR01AI181682 · NIAID · EMORY UNIVERSITY · PI Eleftherios Michailidis · 2024 to 2026
$2.1M
Impact of HIV co-infections and comorbidities on circadian rhythm in the liverDP1DK139804 · NIDDK · EMORY UNIVERSITY · PI Eleftherios Michailidis · 2024 to 2026
$1.7M
Elucidating the host and viral determinants of treatment response in chronic hepatitis BR01AI190067 · NIAID · ROCKEFELLER UNIVERSITY · PI Ype Peter De Jong, Eleftherios Michailidis · 2026 to 2026
$863k
Virus-host interactions for a cure against HBVR56AI182395 · NIAID · EMORY UNIVERSITY · PI MICHAILIDIS, ELEFTHERIOS · 2024 to 2024
$510k
NCATS NIH HHS UL1 TR001866NCCIH NIH HHS U01 AT012984NHLBI NIH HHS R01 HL131093NIAID NIH HHS R01 AI150275NIAID NIH HHS R01 AI181682NIAID NIH HHS R01 AI183884NIAID NIH HHS R01 AI190067NIAID NIH HHS R56 AI182395NIDDK NIH HHS DP1 DK139804
6 · The paper itself

Abstract

Background: Hepatitis B virus (HBV) basal core promoter (BCP) and precore (PC) mutations occur during chronic HBV infection with the BCP-mutant being associated with increased hepatocellular carcinoma (HCC) risk. Objectives: The effects of these mutants on viral replication, hepatocyte biology, and carcinogenesis remain poorly defined. To address this, we characterized BCP- and PC-mutants using human hepatocyte chimeric mice and asked whether the resulting infection-induced transcriptomes correspond to subsets of human HBV-related hepatocellular carcinomas (HBV-HCCs). Design: Isogenic wild-type (WT), BCP- and PC-mutants of HBV genotypes A, C, and D (HBV-A, -C, -D) were generated from recombinant covalently-closed circular DNA to infect chimeric mice. HBV-HCC transcriptomic datasets from The Cancer Genome Atlas (TCGA) were used to stratify association of HBV variants with HCC subtypes. Results: WT, BCP-mutant, and PC-mutant HBV sequences remained genetically stable. The BCP mutation, but not the PC mutation, accelerated the rise in serum viremia in HBV-D- and HBV-A-infected chimeras; in HBV-C, acceleration required both (PC+BCP) mutations. Further comparisons of HBV-D variants revealed that the BCP-mutant increased intrahepatic viral DNA, viral protein expression, and upregulated cancer-related pathways, including transcripts associated with a subset of HBV-HCCs. Analysis of HBV-HCC samples from the TCGA revealed that tumors often harbor a mixture of WT and mutant transcripts, and that WT- and BCP-mutant-associated HCCs exhibit distinct transcriptional profiles. Conclusions: The HBV BCP-mutant directly perturbs hepatocyte homeostasis via virus-intrinsic mechanisms, selectively activating cancer-related pathways and defining a molecularly distinct subset of HBV-HCC. These findings suggest that HBV variants form distinct subcategories of HBV-HCCs.

Indexed as

hepatitis B virushepatocellular carcinomaviral hepatitis

Identifiers

PMID42818274
PMCPMC13622158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.